Search clinical trials for: 4SC-202

Total 4456 results

TScan Therapeutics, Inc.

Recruiting

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Melanoma | Cervical Cancer | Head and Neck Cancer | HPV-Related Malignancy | Ovarian Cancer | HPV-Related Carcinoma | HPV-Related Cervical Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Non-small Cell Carcinoma | HPV - Anogenital Human Papilloma Virus Infection | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma and other conditions

United States
4SC AG

Completed

Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)

Advanced Hematologic Malignancies

Germany
4SC AG

Completed

Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies (AEGIS)

Malignant Lymphomas | Advanced and Incurable Solid Tumors

Germany
4SC AG

Completed

Single Dose Study With 4SC-203 in Healthy Volunteers

Acute Myeloid Leukemia

Germany
4SC AG

Active, not recruiting

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (RESMAIN)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides | Sezary Syndrome

Austria, Spain, Germany, United Kingdom, France, Belgium, Japan, Switzerland, Italy, Poland, Netherlands, Greece
4SC AG

Completed

4SC-201 (Resminostat) in Advanced Colorectal Carcinoma (SHORE)

Advanced Colorectal Carcinoma

Germany
4SC AG

Completed

Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma (SAPHIRE)

Hodgkin's Lymphoma

Poland, Czech Republic, Romania
Royal Marsden NHS Foundation Trust
Merck KGaA, Darmstadt, Germany; 4SC AG

Unknown

Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE) (EMERGE)

Cancer | GI Cancer

United Kingdom
The University of Hong Kong

Not yet recruiting

Adjunctive Effect of Acupuncture for Advanced Cancer Patients With Palliative Care: a Three-arm Randomized Trial

Advanced Cancer
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

Parkinson's Disease

Switzerland
4SC AG

Completed

4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE)

Malignant Melanoma

Germany, Italy
Karolinska University Hospital
Swedish Foundation for Strategic Research

Recruiting

A Study of Local Administration of Autologous Mesenchymal Stromal Cells in Dysphonic Patients With Vocal Fold Scarring

Dysphonia | Hoarseness | Aphonia | Vocal Fold; Scar

Sweden
Hookipa Biotech GmbH

Recruiting

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

HPV-Related Squamous Cell Carcinoma

United States, Spain, Netherlands
University of Aarhus
Aarhus University Hospital

Completed

TReatment Strategy In Acute Ischemic larGE Vessel STROKE: Prioritize Thrombolysis or Endovascular Treatment (TRIAGE)

Stroke

Denmark
Stemcentrx

Terminated

SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma

Small Cell Lung Cancer

United States
ARYx Therapeutics

Completed

Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers

Atrial Fibrillation

United States, Canada
Celgene

Completed

Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

Healthy

United States
4SC AG

Completed

4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma (Shelter)

Hepatocellular Carcinoma

Germany, Italy
Vanderbilt University Medical Center
Patient-Centered Outcomes Research Institute; University of Alabama at Birmingham

Enrolling by invitation

Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Stroke Care (C3FIT)

Stroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke Hemorrhagic

United States
Yusuf Menda
National Cancer Institute (NCI); National Institutes of Health (NIH); Holden...

Not yet recruiting

A Safety Study of 212Pb-Pentixather Radioligand Therapy

Carcinoid Tumor Lung | Neuroendocrine Tumor of the Lung | Carcinoma, Small-Cell Lung

United States
University Medicine Greifswald

Active, not recruiting

Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI) ((AIGI))

Seasonal Influenza Vaccination

Germany
4SC AG

Completed

SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease (ENTRANCE)

Inflammatory Bowel Disease (IBD)

Germany, Bulgaria, Romania
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity

Melanoma

United States
Evofem Inc.
Neothetics, Inc

Terminated

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

Central Abdominal Bulging
REGENXBIO Inc.

Recruiting

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States
Alpine Immune Sciences, Inc.

Terminated

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)

Lymphoma | Advanced Solid Tumor

United States, Australia
GenSpera, Inc.

Completed

Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme

United States
GenSpera, Inc.

Completed

Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Neothetics, Inc

Unknown

An Open-Label Study to Evaluate Retreatment With LIPO-202

Central Abdominal Bulging

United States
Uppsala University
Uppsala University Hospital

Active, not recruiting

Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome (ARDS-MSC-205)

COVID | ARDS, Human

Sweden
Sarang K. Yoon, DO, MOH
Novavax; Westat

Recruiting

The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection (BEEHIVE)

COVID-19 | SARS CoV 2 Infection | Vaccine-Preventable Diseases | Upper Respiratory Tract Infection | Upper Respiratory Disease

United States
McMaster University
Canadian Institutes of Health Research (CIHR)

Recruiting

Relative Impacts on Preventative Primary Care--a Longitudinal Evaluation of COVID-19:Phase 1 (RIPPLE-C)

Diabetes Mellitus | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Osteoarthritis | Dementia | Congestive Heart Failure | Depression, Anxiety

Canada
ILIAS Biologics Inc.

Completed

A Study to Evaluate the Safety and Tolerability of ILB-202

Healthy

Australia
Akron Molecules AG

Completed

A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain

Osteoarthritis

Austria
Devalingam Mahalingam
GenSpera, Inc.

No longer available

Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
GenSpera, Inc.

Withdrawn

Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer.

United States
Immune-Onc Therapeutics
California Institute for Regenerative Medicine (CIRM)

Recruiting

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

CMML | AML With Monocytic Differentiation

United States
Oui Therapeutics, Inc.
National Institute of Mental Health (NIMH)

Enrolling by invitation

A Study to Evaluate the Safety and Effectiveness of a Digital Therapeutic

Suicidal Ideation | Suicide, Attempted

United States
Inversago Pharma Inc.

Active, not recruiting

Study of INV-202 in Patients With Obesity and Metabolic Syndrome

Obesity | Metabolic Syndrome

Canada
Inversago Pharma Inc.

Completed

A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome

Metabolic Syndrome

Canada
GenSpera, Inc.

Completed

Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA

Clear Cell Renal Cell Carcinoma

United States
GenSpera, Inc.

Completed

G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer

Prostatic Neoplasms

United States
GenSpera, Inc.
Saint John's Cancer Institute

Withdrawn

Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma

Glioblastoma

United States
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

Melanoma (Skin)

United States
Seoul National University Hospital

Completed

NuGa (Nutrition for Gastric Cancer Patients)

Gastric Cancer

Korea, Republic of
Bial - Portela C S.A.

Completed

Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202

Parkinson's Disease

United Kingdom
Canopy Growth Corporation

Completed

Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity

Delayed Onset Muscle Soreness (DOMS)

United States
Northwestern University
Brain & Behavior Research Foundation; Neurocentria, Inc.

Completed

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States

Search clinical trials for: 4SC-202

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations